Phase 3 Clinical Trials With Primary Completion Dates in March 2019

This is a list of Phase 3 trials with primary completion dates in March 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ASNDAscendis Pharma A/S2019-03-01Phase 3NCT03305016A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
ASNDAscendis Pharma A/S2019-03-01Phase 3NCT02781727A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
CARACara Therapeutics, Inc.2019-03-01Phase 3NCT03422653A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
CPRXCatalyst Pharmaceuticals, Inc.2019-03-01Phase 3NCT03304054Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
FGENFibroGen, Inc2019-03-01Phase 3NCT03263091Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden
KMPHKemPharm, Inc.2019-03-01Phase 3NCT03460652KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
NVAXNovavax, Inc.2019-03-01Phase 3NCT02624947A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
ONTXOnconova Therapeutics, Inc.2019-03-01Phase 3NCT02562443Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
SNGXSoligenix, Inc.2019-03-01Phase 3NCT03237325DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
SNYSanofi2019-03-01Phase 3NCT02926950Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
SUPNSupernus Pharmaceuticals, Inc.2019-03-01Phase 3NCT02691182Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
XERSXeris Pharmaceuticals, Inc.2019-03-01Phase 3NCT03738865G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
ZSANZosano Pharma Corporation2019-03-01Phase 3NCT03282227A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine